Compare DexCom, Inc. (DXCM) vs Lumen Technologies Inc (LUMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Lumen Technologies Inc — how do they compare? DexCom, Inc. trades at $77.79 (market cap $28.06B), while Lumen Technologies Inc trades at $6.31 (market cap $6.56B). The key difference: DexCom, Inc. is far larger — about 4.3× Lumen Technologies Inc's market cap, and DexCom, Inc. is trading nearer its 52-week high, Lumen Technologies Inc nearer its low. Which is the better fit depends on your goals.
| DXCM | LUMN | |
|---|---|---|
Market Cap | $28.06B | $6.56B |
Sector | Health | Media |
52-Week High | $89.53 | $11.83 |
52-Week Low | $54.84 | $3.70 |
Enterprise Value | $27.03B | $18.19B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.
The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.
LUMN trades at $6.37, showing no change recently, with a bearish technical signal and mixed earnings history. The company reported a net loss of $1.74B in 2025, though revenue remains substantial at $12.40B. Recent developments include the acquisition of Alkira to enhance AI networking capabilities and cost-cutting initiatives targeting $1B in savings by 2027. Analyst consensus is cautious, with a hold-heavy rating distribution and a $8.25 price target.
The outlook is challenging due to persistent losses and high debt, but strategic acquisitions and efficiency efforts offer potential upside. Risks include execution hurdles and competitive pressures in telecom. Investors should weigh the low P/S ratio against profitability concerns before considering a position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Lumen Technologies Inc
With 450,000 route miles of fiber, including over 35,000 route miles of subsea fiber connecting Europe, Asia, and Latin America, Lumen Technologies is one of the United States' largest telecommunications carriers serving global enterprises. Its merger with Level 3 further shifted the company's operations toward businesses (over 70% of revenue) and away from its legacy consumer business. Lumen offers businesses a full menu of communications services, providing colocation and data center services, data transportation, and end-user phone and internet service. On the consumer side, Lumen provides broadband and phone service across 37 states, where it has 4.5 million broadband customers.
Read more on LUMN →
